CS251060B2 - 9-(hydroxyalkyl)purines' derivatives salts production method - Google Patents

9-(hydroxyalkyl)purines' derivatives salts production method Download PDF

Info

Publication number
CS251060B2
CS251060B2 CS796226A CS622679A CS251060B2 CS 251060 B2 CS251060 B2 CS 251060B2 CS 796226 A CS796226 A CS 796226A CS 622679 A CS622679 A CS 622679A CS 251060 B2 CS251060 B2 CS 251060B2
Authority
CS
Czechoslovakia
Prior art keywords
formula
compound
same meaning
point
amine
Prior art date
Application number
CS796226A
Other languages
Czech (cs)
English (en)
Inventor
Lionel N Simon
John W Hadden
Original Assignee
Newport Pharmaceuticals
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newport Pharmaceuticals, Sloan Kettering Inst Cancer filed Critical Newport Pharmaceuticals
Publication of CS251060B2 publication Critical patent/CS251060B2/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36Sulfur atom
    • C07D473/38Sulfur atom attached in position 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CS796226A 1978-09-15 1979-09-14 9-(hydroxyalkyl)purines' derivatives salts production method CS251060B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/942,802 US4221909A (en) 1978-09-15 1978-09-15 P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines

Publications (1)

Publication Number Publication Date
CS251060B2 true CS251060B2 (en) 1987-06-11

Family

ID=25478620

Family Applications (1)

Application Number Title Priority Date Filing Date
CS796226A CS251060B2 (en) 1978-09-15 1979-09-14 9-(hydroxyalkyl)purines' derivatives salts production method

Country Status (27)

Country Link
US (1) US4221909A (es)
EP (1) EP0009154B1 (es)
JP (1) JPS5547683A (es)
KR (1) KR840000552A (es)
AT (1) ATE1949T1 (es)
AU (1) AU527851B2 (es)
CA (1) CA1122217A (es)
CS (1) CS251060B2 (es)
DD (1) DD146049A5 (es)
DE (1) DE2964211D1 (es)
DK (1) DK149857C (es)
ES (1) ES484167A1 (es)
FI (1) FI68234C (es)
GR (1) GR74076B (es)
HU (1) HU182544B (es)
IE (1) IE48827B1 (es)
IL (1) IL58087A (es)
IN (1) IN153099B (es)
MX (1) MX6521E (es)
NO (1) NO152445C (es)
NZ (1) NZ191483A (es)
PH (1) PH16315A (es)
PL (2) PL124515B1 (es)
PT (1) PT70180A (es)
RO (1) RO77565A (es)
YU (1) YU41884B (es)
ZA (1) ZA793973B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340726A (en) * 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
US4849411A (en) * 1982-11-09 1989-07-18 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5147636A (en) * 1982-11-09 1992-09-15 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives and interferons
HUT36464A (en) * 1983-05-24 1985-09-30 Newport Pharmaceuticals Process for producing erythro-4-amino-3-/2-hydroxy-3-alkyl/-imidazol-5-carboxamide
IT1215339B (it) * 1987-01-14 1990-02-08 Co Pharma Corp Srl Procedimento per la preparazione di 9-(idrossialchil)-ipoxantine
US5091432A (en) * 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
PL318293A1 (en) 1994-07-25 1997-06-09 Alvin J Glasky Carbon monoxide dependent guanilyl cyclase modifiers
CA2199615A1 (en) * 1996-02-12 1997-08-14 Elie Abushanab Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits
AU3786299A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel serotonin-like 9-substituted hypoxanthine and methods of use
US6297226B1 (en) 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US6849735B1 (en) 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
ATE499103T1 (de) 2000-07-07 2011-03-15 Spectrum Pharmaceuticals Inc Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
CA2540598C (en) * 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
WO2005074946A1 (en) * 2004-02-10 2005-08-18 Adenobio N.V. Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3215696A (en) * 1965-11-02 Substituted adenines -and preparation thereof
US3728450A (en) * 1969-08-28 1973-04-17 Newport Pharmaceuticals Inosine derivatives
BE755361A (fr) * 1969-08-28 1971-03-01 Newport Pharmaceuticals Derives de l'inosine
US3857940A (en) * 1971-05-21 1974-12-31 Newport Pharmaceuticals Inosine derivatives
US3836656A (en) * 1972-02-07 1974-09-17 Sandoz Ag Substituted purines as hypolipidemics
US3862189A (en) * 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
US4060616A (en) * 1976-03-01 1977-11-29 Burroughs Wellcome Co. Purine derivatives with repeating unit
YU96177A (en) * 1976-04-24 1982-08-31 Wuelfing Johann A Process for obtaining adenine derivatives

Also Published As

Publication number Publication date
IE791753L (en) 1980-03-15
PL119685B1 (en) 1982-01-30
AU527851B2 (en) 1983-03-24
AU5055779A (en) 1980-03-20
IE48827B1 (en) 1985-05-29
CA1122217A (en) 1982-04-20
ES484167A1 (es) 1980-09-01
YU41884B (en) 1988-02-29
PT70180A (en) 1979-10-01
NO792792L (no) 1980-03-18
ATE1949T1 (de) 1982-12-15
PL124515B1 (en) 1983-01-31
NZ191483A (en) 1983-06-14
EP0009154B1 (en) 1982-12-08
YU224579A (en) 1983-12-31
RO77565A (ro) 1981-11-04
NO152445B (no) 1985-06-24
US4221909A (en) 1980-09-09
FI792849A (fi) 1980-03-16
IL58087A (en) 1983-03-31
KR840000552A (ko) 1984-02-25
EP0009154A1 (en) 1980-04-02
DK149857B (da) 1986-10-13
DD146049A5 (de) 1981-01-21
GR74076B (es) 1984-06-06
PH16315A (en) 1983-09-05
ZA793973B (en) 1980-09-24
JPH031309B2 (es) 1991-01-10
DK149857C (da) 1987-03-02
FI68234C (fi) 1985-08-12
FI68234B (fi) 1985-04-30
DK385679A (da) 1980-03-16
NO152445C (no) 1985-10-02
HU182544B (en) 1984-02-28
DE2964211D1 (en) 1983-01-13
IN153099B (es) 1984-06-02
JPS5547683A (en) 1980-04-04
MX6521E (es) 1985-06-27
PL218317A1 (es) 1980-06-16

Similar Documents

Publication Publication Date Title
CS251060B2 (en) 9-(hydroxyalkyl)purines' derivatives salts production method
Gresser et al. Increased survival in mice inoculated with tumor cells and treated with interferon preparations
US4221794A (en) Method of imparting immunomodulating and antiviral activity
Ennis et al. Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells
US4279892A (en) Organogermanium induction of interferon production
Djeu et al. Augmentation of mouse natural killer activity and induction of interferon by tumor cells in vivo.
Isaacs et al. Studies on the mechanism of action of interferon
JPH031310B2 (es)
Hilleman Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man
JPH03504122A (ja) 抗ウイルス・抗腫瘍・抗転移・免疫系増強ヌクレオシド類およびヌクレオチド類
NL9000265A (nl) Ethyl-6-broom-5-hydroxy-4-dimethylaminomethyl-1-methyl-2-fenylthiomethylindool-3-carboxylaat-hydrochloride-monohydraat, werkwijze voor de bereiding ervan en een farmaceutisch preparaat dat deze stof bevat, met antivirale, interferon inducerende en immunomodulatoire effecten.
Ilan et al. Effects of colchicine on nucleic acid metabolism during metamorphosis of Tenebrio molitor L. and in some mammalian tissues
CN101370783B (zh) 9-氧代吖啶-10-乙酸和1-烷基氨基-1-脱氧多羟基化合物的盐和混合物、包含其的药物组合物以及治疗方法
AU636574B2 (en) Method of using plant nucleoside derivatives for treatment of viral infections
Gazdar et al. Interferon inducers: enhancement of viral oncogenesis in mice and rats
Renoux et al. Isoprinosine as an immunopotentiator
Miller et al. Antiviral activity of carbobenzoxy di-and tripeptides on measles virus
RU2036198C1 (ru) N-МЕТИЛ-N-( α,D -ГЛЮКОПИРАНОЗИЛ) АММОНИЯ-2-(АКРИДОН-9-ОН-10-ИЛ)АЦЕТАТ(ЦИКЛОФЕРОН), ОБЛАДАЮЩИЙ ИНТЕРФЕРОНОГЕННОЙ, ПРОТИВОВИРУСНОЙ, В ТОМ ЧИСЛЕ АНТИВИЧ, АНТИПАРАЗИТАРНОЙ, АНТИПРОМОТОРНОЙ И РАДИОПРОТЕКТИВНОЙ АКТИВНОСТЬЮ
EP0739208A1 (en) Flavin derivatives as anti-viral agents
IT9048102A1 (it) Derivati oligopeptidici dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono
Spivack et al. Dissociation of the inhibitory effects of 2-deoxy-D-glucose on Vero cell growth and the replication of herpes simplex virus
DEGRæ et al. Interferon induction in human cell cultures by small molecular inducers (tilorone and acridines)
Huffman et al. Lack of suppression of resistance factors to influenxa infections in mice pretreated with virazole
World Health Organization Interferon and other antiviral agents, with special reference to influenza: a memorandum
JPS63107924A (ja) 抗レトロウイルス剤